AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28254462 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3652 300 mg twice daily
Number of subjects: 239
Study 28254462 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3652 75 mg, 150 mg, or 300 mg once daily
Number of subjects: 239
Study 28254462 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3652 (all doses)
Number of subjects: 239
Study 26457036 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopes
Number of subjects: 104
Study 26457036 — intervention group
Group type: COMPARATOR
Intervention: Other refractive groups (hyperopes, emmetropes, lower myopes)
Number of subjects: 104
Study 23480601 — intervention group
Group type: EXPERIMENTAL
Intervention: Retained presumed intraocular cotton fibers
Number of subjects: 14
Study 23480601 — intervention group
Group type: COMPARATOR
Intervention: No postoperative intraocular cotton fibers (Control)
Number of subjects: 14
Study 21547897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) treatment for 12 months
Number of subjects: 0
Study 21547897 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with 50% or more lung zone involvement by reticular infiltrates and MRSS of at least 23
Number of subjects: 0
Study 21547897 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with less severe HRCT findings and lower MRSS at baseline
Number of subjects: 0
Study 18001798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical pentosan polysulfate sodium plus oral pentosan polysulfate sodium
Number of subjects: 41
Study 18001798 — intervention group
Group type: COMPARATOR
Intervention: Intravesical placebo plus oral pentosan polysulfate sodium
Number of subjects: 41
Study 18001798 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 41
Study 18001798 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 41
Study 18001798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 16818861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 25
Study 16818861 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 25
Study 14602435 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-initiated oral prednisolone (20 mg once daily for 5 days)
Number of subjects: 153
Study 14602435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 10759619 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin with omeprazole
Number of subjects: 12
Study 10759619 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin with lansoprazole
Number of subjects: 12
Study 8821390 — intervention group
Group type: EXPERIMENTAL
Intervention: M+S condition (voluntary movements of the right index finger triggering electrical stimulus)
Number of subjects: 5
Study 8821390 — intervention group
Group type: EXPERIMENTAL
Intervention: Task SEFs (during electrical stimulation of the right index finger)
Number of subjects: 5
Study 8821390 — intervention group
Group type: COMPARATOR
Intervention: Control SEFs (recorded at the beginning of the experiment during rest)
Number of subjects: 5
Study 1434725 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg)
Number of subjects: 65
Study 1434725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 4020257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 5
Study 30825795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Number of subjects: 517
Study 30825795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Number of subjects: 517
Study 30825795 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided Quit Attempts
Number of subjects: 517
Study 30825795 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaided Quit Attempts
Number of subjects: 517
Study 29274660 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Awareness
Number of subjects: 135
Study 29274660 — intervention group
Group type: COMPARATOR
Intervention: Promise
Number of subjects: 135
Study 29274660 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 27055257 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical device (MD; a capsule whose main component is a cross‐linked protein)
Number of subjects: 0
Study 27055257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg/day and 1 capsule/day
Number of subjects: 0
Study 27055257 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 24665980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/d
Number of subjects: 30
Study 24665980 — intervention group
Group type: COMPARATOR
Intervention: Control group (Transmetil 1000 mg/d or Essentiale 1368 mg/d)
Number of subjects: 30
Study 22462425 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 40
Study 22462425 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 40
Study 22462425 — intervention group
Group type: COMPARATOR
Intervention: Both diclofenac and naproxen
Number of subjects: 40
Study 20401617 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week elimination diet
Number of subjects: 27
Study 20401617 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 27
Study 17519049 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam 16 mg
Number of subjects: 57
Study 17519049 — intervention group
Group type: COMPARATOR
Intervention: tenoxicam 40 mg
Number of subjects: 57
Study 15226623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg/day) plus aspirin (81 mg/day)
Number of subjects: 282
Study 15226623 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol (200 mg/day) plus aspirin (81 mg/day)
Number of subjects: 282
Study 15226623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 282
Study 15226623 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 282
Study 11285053 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 9
Study 11285053 — intervention group
Group type: EXPERIMENTAL
Intervention: SWS interruption
Number of subjects: 9
Study 11285053 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep interruption
Number of subjects: 9
Study 11285053 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep after SWS interruption
Number of subjects: 9
Study 11285053 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep after REM sleep interruption
Number of subjects: 9
Study 11285053 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal pain thresholds
Number of subjects: 9
Study 9824569 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 300
Study 9824569 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 300
Study 9824569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 7925336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg kg‐1 and atropine 0.02 mg kg‐1 intramuscularly 90 min prior to surgery (n = 10)
Number of subjects: 20
Study 7925336 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg kg‐1 and atropine 0.02 mg kg‐1 orally, 120 min before surgery (n = 10)
Number of subjects: 20
Study 7925336 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (Pethidine and Midazolam)
Number of subjects: 20
Study 2697552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (19 g anhydrous)
Number of subjects: 7
Study 2697552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (19 g)
Number of subjects: 7
Study 2697552 — intervention group
Group type: COMPARATOR
Intervention: Other test compounds (Sorbitol 10 g, Mannitol 10 g, Maltitol 19 g, Palatinit 19 g anhydrous)
Number of subjects: 7
Study 998555 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fiber added to metabolically‐controlled diets for 3 weeks
Number of subjects: 6
Study 31076287 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit balance board exercise program (yoga, strength training, aerobic exercise)
Number of subjects: 0
Study 31076287 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer exercise training
Number of subjects: 0
Study 28183583 — intervention group
Group type: EXPERIMENTAL
Intervention: Red group (NRS questionnaire printed on red paper)
Number of subjects: 200
Study 28183583 — intervention group
Group type: COMPARATOR
Intervention: Green group (NRS questionnaire printed on green paper)
Number of subjects: 200
Study 28183583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on antidepressants (n=76)
Number of subjects: 200
Study 28183583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression (n=49)
Number of subjects: 200
Study 26308946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 70
Study 26308946 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 70
Study 23547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg
Number of subjects: 48
Study 23547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg with rHuPH20
Number of subjects: 48
Study 23547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 324 mg with rHuPH20
Number of subjects: 48
Study 23547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 648 mg with rHuPH20
Number of subjects: 48
Study 23547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of tocilizumab
Number of subjects: 48
Study 23547849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab with and without rHuPH20
Number of subjects: 48
Study 21714883 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention involving comprehensive assessment of medical and non-medical needs, regular structured monitoring of symptoms, written information, symptom diaries, action plans, and a medication plan for self-management capabilities.
Number of subjects: 0
Study 21714883 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 19798550 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Binomial (NB) model
Number of subjects: 551
Study 19798550 — intervention group
Group type: EXPERIMENTAL
Intervention: Markovian features in lambda and overdispersion parameter
Number of subjects: 551
Study 19798550 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-Inflated Poisson (ZIP) model
Number of subjects: 551
Study 19798550 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-Inflated Negative Binomial (ZINB) model
Number of subjects: 551
Study 19798550 — intervention group
Group type: COMPARATOR
Intervention: Poisson distribution (PS) model
Number of subjects: 551
Study 16246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) with 50.4 Gy and fluorouracil in the first and fifth week
Number of subjects: 385
Study 16246976 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 4 (complete response)
Number of subjects: 385
Study 16246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped TRG 2 + 3 (intermediate response)
Number of subjects: 385
Study 16246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped TRG 0 + 1 (poor response)
Number of subjects: 385
Study 12390096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod, 6 mg b.d. (n = 767)
Number of subjects: 1519
Study 12390096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 752)
Number of subjects: 1519
Study 10191213 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate HIV-1 vaccine
Number of subjects: 0
Study 10191213 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza expansion
Number of subjects: 0
Study 10191213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Number of subjects: 0
Study 7762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Megatherapy followed by autologous bone marrow transplantation (MGT/ABMT) in Ewing's sarcoma patients
Number of subjects: 2085
Study 7762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Megatherapy followed by autologous bone marrow transplantation (MGT/ABMT) in germ cell tumor patients
Number of subjects: 2085
Study 7762255 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery, megatherapy (BCNU)/ABMT, and radiotherapy in malignant brain gliomas
Number of subjects: 2085
Study 2263428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (52 doses)
Number of subjects: 76
Study 2263428 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (94 doses)
Number of subjects: 76
Study 2263428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (A and B)
Number of subjects: 76
Study 7457179 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopaque Cerebral (meglumine‐ca‐metrizoate)
Number of subjects: 0
Study 7457179 — intervention group
Group type: COMPARATOR
Intervention: Amipaque (metrizamide)
Number of subjects: 0
Study 30109443 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond (CU)
Number of subjects: 18
Study 30109443 — intervention group
Group type: EXPERIMENTAL
Intervention: iBOND Universal (IU)
Number of subjects: 18
Study 30109443 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐Premio Bond (GP)
Number of subjects: 18
Study 28000034 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 24
Study 28000034 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 24
Study 25881458 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture based on infants development theory
Number of subjects: 120
Study 25881458 — intervention group
Group type: COMPARATOR
Intervention: Head acupuncture (control group)
Number of subjects: 120
Study 23605128 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy (EST) on the suprahyoid muscle only (SM)
Number of subjects: 50
Study 23605128 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy (EST) with one pair of electrodes on the suprahyoid muscle and another pair on the infrahyoid muscle (SI)
Number of subjects: 50
Study 23605128 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SM and SI groups
Number of subjects: 50
Study 21967798 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐TURP+ILC
Number of subjects: 150
Study 21967798 — intervention group
Group type: EXPERIMENTAL
Intervention: ILC
Number of subjects: 150
Study 21967798 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 150
Study 20066873 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital multimedia instruction (DVD)
Number of subjects: 2
Study 20066873 — intervention group
Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 2
Study 17605534 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic violent video game
Number of subjects: 112
Study 17605534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantasy violent video game
Number of subjects: 112
Study 17605534 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 112
Study 14988623 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 14988623 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 11805412 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with interstitial cystitis (IC)
Number of subjects: 30
Study 11805412 — intervention group
Group type: COMPARATOR
Intervention: Control patients (non-IC)
Number of subjects: 30
Study 9517646 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day low dose triple therapy (LAT group): lansoprazole 30 mg b.i.d. on days 1-4, azithromycin 500 mg u.i.d. on days 2-4, tinidazole 2000 mg u.i.d. on day 3
Number of subjects: 160
Study 9517646 — intervention group
Group type: COMPARATOR
Intervention: 1-week triple therapy (OCT group): omeprazole 20 mg u.i.d., clarithromycin 250 mg b.i.d., tinidazole 500 mg b.i.d.
Number of subjects: 160
Study 7922791 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral strength training at 80% one repetition maximum for 1 year
Number of subjects: 12
Study 7922791 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining for 3 months
Number of subjects: 12
Study 7922791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study 3132244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen and progestogen (continuous supplementation)
Number of subjects: 0
Study 3132244 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen and progestogen (sequential supplementation)
Number of subjects: 0
Study 3132244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29191714 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulins
Number of subjects: 46
Study 29191714 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 46
Study 28176220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoids (ivGCs) - methylprednisolone with cumulative doses of 2.25, 4.98, 7.47 g
Number of subjects: 159
Study 25456613 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CSPS dentifrice
Number of subjects: 20
Study 25456613 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (fluoride-only)
Number of subjects: 20
Study 22622819 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised specific strength exercises for the neck and shoulder muscles for 20 minutes three times a week (n=282)
Number of subjects: 537
Study 22622819 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n=255)
Number of subjects: 537
Study 21934371 — intervention group
Group type: EXPERIMENTAL
Intervention: P group (random surface tilt perturbations, 3 times weekly for 3 weeks)
Number of subjects: 29
Study 21934371 — intervention group
Group type: EXPERIMENTAL
Intervention: P+EX group (random surface tilt perturbations + home vestibular rehabilitation exercises, 3 times weekly for 3 weeks)
Number of subjects: 29
Study 21934371 — intervention group
Group type: COMPARATOR
Intervention: EX group (only vestibular rehabilitation exercises)
Number of subjects: 29
Study 21934371 — intervention group
Group type: EXPERIMENTAL
Intervention: P and P+EX groups (combined)
Number of subjects: 29
Study 19145673 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen i.v. every 8h for 72h
Number of subjects: 60
Study 19145673 — intervention group
Group type: COMPARATOR
Intervention: 2.5 g metamizole i.v. every 8h for 72h
Number of subjects: 60
Study 16902267 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 36
Study 16902267 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail education
Number of subjects: 36
Study 16902267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 12042687 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week hospital-based angina management program (n = 75)
Number of subjects: 226
Study 12042687 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 74)
Number of subjects: 226
Study 12042687 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (n = 77)
Number of subjects: 226
Study 12042687 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 226
Study 10505582 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 1460
Study 10505582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study 8562627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat intake 12-24 months before diagnosis
Number of subjects: 96
Study 8562627 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of calories as fat 12-24 months before diagnosis
Number of subjects: 96
Study 8562627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat consumption 0-12 months prediagnostic interval
Number of subjects: 96
Study 1940775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg nightly in non-FH patients
Number of subjects: 232
Study 1940775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly in FH patients
Number of subjects: 232
Study 1940775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg nightly in pooled patients (n = 224)
Number of subjects: 232
Study 1940775 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin treatment
Number of subjects: 232
Study 7007666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 265
Study 7007666 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 265
Study 30142301 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children (MATCH)
Number of subjects: 55
Study 29072430 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model (HBM) conducted in five sessions with group discussions and training videos.
Number of subjects: 92
Study 29072430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 92
Study 24787312 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning pressure‐based sensor (FPS)
Number of subjects: 67
Study 24787312 — intervention group
Group type: COMPARATOR
Intervention: Nonfunctioning sensor (NFPS)
Number of subjects: 67
Study 24787312 — intervention group
Group type: COMPARATOR
Intervention: No sensor (NS)
Number of subjects: 67
Study 24264781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 123
Study 24264781 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 123
Study 21318412 — intervention group
Group type: EXPERIMENTAL
Intervention: BALANCE intervention (Motivational Interviewing plus feedback)
Number of subjects: 228
Study 21318412 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 228
Study 19056606 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 2 g once daily
Number of subjects: 81
Study 19056606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81